Concourse Financial Group Securities, Inc. Alzamend Neuro, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.64 Billion
  • Q3 2024

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 30, 2023
BUY
$0.19 - $0.52 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023
BUY
$0.19 - $0.52 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023
BUY
$0.49 - $0.77 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023
BUY
$0.37 - $0.71 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$0.53 - $222.0 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$0.88 - $178.5 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$0.82 - $1.2 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$0.91 - $2.23 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$1.9 - $3.08 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$2.28 - $7.68 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$8.12 - $13.5 $0 - $0
0 New
0 $0

About Alzamend Neuro, Inc.

ALZN Quotes by TradingView
  • Ticker ALZN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 95,481,800
  • Market Cap $115M
  • Description
  • Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...
More about ALZN
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email